Turkey's health ministry has applied to the country's official Medicines and Medical Devices Agency (TITCK) for emergency authorisation of its domestically developed COVID-19 vaccine, Turkovac, Reuters news agency reported on Thursday.
Health minister Fahrettin Koca told parliament that work on Turkovac was nearing completion and added the vaccine would mark the first Phase III clinical research project to be fully carried out by Turkey.
The vaccine is expected to be available for use by the end of the year.
Turkish President Tayyip Erdogan has said that the country would make the shot available globally.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA